BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of Teva Pharmaceutical Industries Ltd. (“Teva” or the “Company”) (NYSE: TEVA) investors concerning the Company and its officers’ possible violations of federal securities laws.
On August 2, 2016, Teva finalized its acquisition of Allergan plc’s generics business, Actavis Generis. Teva continued to make positive statements concerning the integration of the business, growth on intangible assets and goodwill, and general benefits of the acquisition. Thereafter, on August 3, 2017, Teva lowered its outlook and recorded a $6.1 billion impairment charge.
If you purchased Teva securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020 by telephone at (215) 638-4847, toll-free at (888) 638-4847, or by email to email@example.com, or visit our website at www.howardsmithlaw.com.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.